EUCTR2012-003006-27-DE进行中（未招募）不适用
A Phase II, Multicentre, Multinational, Randomised, Assessor-Blind Trial to Investigate the Efficacy and Safety of Various Dosages of FSH-GEX™ in Comparison With 150 IU Gonal-f® in Women Undergoing ICSI Treatment
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Female patient for whom ICSI treatment is justified at the investigator`s discretion and who is willing to undergo ICSI treatment using ejaculated sperm.
- •2.Aged 18 – 37 years at Screening.
- •3.Serum follicle-stimulating hormone (FSH) concentration = 12 IU/l measured between Day 1 and Day 5 of a spontaneous menstrual cycle. Measured within six months before randomisation.
- •4.Anti-mullerian hormone (AMH): 1 - 4 ng/ml. Measured within six months before randomisation.
- •5.Antral follicle count (sum of both ovaries): = 7 and = 20.
- •6.Body mass index (BMI) 18.5-30 kg/m² and body weight = 45 kg and = 90 kg.
- •7.Presence of both ovaries.
- •8.Regular spontaneous cycles between 21 and 35 days in length (intercycle variations not more than ± 5 days).
- •9.Normal uterine cavity as assessed by transvaginal sonography at Screening. No fibroids as assessed by the investigator that would require treatment to facilitate pregnancy.
- •10.Willing and able to comply with the protocol.
- •11.Willing and able to provide written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 240
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patients who had more than two unsuccessful previous assisted reproduction technology (ART) cycles (IVF or ICSI) before inclusion into the study, where unsuccessful is defined as no embryo transfer or no biochemical or clinical pregnancy was achieved.
- •2.Previous poor responders: < 3 oocytes retrieved in previous treatment cycles.
- •3.Patients with previous hyperstimulation syndrome or cycle cancellation because of imminent hyperstimulation syndrome.
- •4.Patients with a history of or current polycystic ovarian morphology (PCO) syndrome) according to the Rotterdam consensus criteria
- •5.Patients with a history of or current endometriosis III or IV according to the American Society for Reproductive Medicine (ASRM) criteria (ASRM, 1996).
- •6.Presence of ovarian cyst at Screening.
- •7.Any contraindication to becoming pregnant.
- •8.History of = 3 clinical or preclinical (absence of gestational sac) miscarriages.
- •9.An abnormal cervical smear (Papanicolaou [PAP] score = 3, obtained within one year prior to randomisation).
- •10.Any history of malignant cancer other than in situ breast or skin cancer requiring local excision.
- •11.Any endocrine abnormalities requiring treatment (latent hypothyroidism treated by thyroxin is allowed).
- •12.Any clinically significant systematic disease, including history of hormonal abnormalities (e.g. Cushing’s syndrome or androgen producing tumours).
- •13.Any known infection with human immunodeficiency virus (HIV), hepatitis B or C.
- •14.History of thrombosis or other risk factors including any coagulation abnormality leading to an increased risk of clotting.
- •15.Family history of genetic risk factors concerning pregnancy or birth.
- •16.Use of concomitant medication, which in the opinion of the investigator might interfere with ICSI preparation procedures.
- •17.Active smoking (no smoking at all allowed) up to four weeks before enrolment in the trial.
- •18.Any active substance abuse of drugs, medications or alcohol within the last five years.
- •19.Patients in an institution by official or court order.
- •20.Patients who are unable or unwilling to provide informed consent.
- •21.Any participation in another clinical trial within the last 60 days before randomisation.
- •22.Previous FSH-GEX™ administration.
- •23.Known hypersensitivity to any component of the investigational and non investigational products used in this study.
研究者
相似试验
进行中（未招募）
不适用
Study to evaluate and compare the efficacy and safety of various doses of FSH-GEX with an accepted comparator in women undergoing intracytoplasmatic sperm injection (ICSI) as part of assisted reproductiowomen undergoing intracytoplasmatic sperm injection (ICSI) as part of assisted reproductionMedDRA version: 14.1Level: LLTClassification code 10016398Term: Female infertilitySystem Organ Class: 100000004872EUCTR2012-003006-27-HUGlycotope GmbH240
进行中（未招募）
1 期
A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeksRelapsing forms of Multiple Sclerosis (RMS)MedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-000284-93-BGMapi Pharma Ltd.1,000
进行中（未招募）
1 期
A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeksRelapsing forms of Multiple Sclerosis (RMS)MedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-000284-93-EEMapi Pharma Ltd.960
进行中（未招募）
不适用
randomized and double-blinded dose finding study to evaluate safety and efficacy of carbabenzpyride compared to placebo in uncomplicated influenza A in multiple centers and countries(Uncomplicated) Influenza AMedDRA version: 13.1Level: LLTClassification code 10022002Term: Influenza A virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-018564-17-ATFarmak International Holding GmbH440
进行中（未招募）
不适用
Randomized and double-blinded dose-finding study to evaluate safety and efficacy of carbabenzpyride compared to placebo in uncomplicated influenza A in multiple centers and countries(Uncomplicated) Influenza AMedDRA version: 13.1Level: LLTClassification code 10022002Term: Influenza A virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-018564-17-DEFarmak International Holding GmbH440